A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF 2 DOSES OF RO4905417 (R1512) ADMINISTERED TO PATIENTS WITH NON ST-ELEVATION MYOCARDIAL INFARCTION (NON-STEMI) UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)
Sponsor: Hoffmann-La Roche
A PHASE2 clinical study on Myocardial Infarction, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 8 data snapshots since 2011. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aurora, United States, Baltimore, United States, Bay City, United States, Bismarck, United States, Boynton Beach, United States, Bydgoszcz, Poland, Chambersburg, United States, Columbus, United States, Edmonton, Canada, Farmington, United States and 51 more location s